Clinically, CD4+ T cells contribute to tumor immunity in diverse ways, including direct cytotoxicity against MHC class II-expressing tumor cells, supporting CD8+ T cell responses, and enhancing the efficacy of immune checkpoint blockade therapies [120, 124]. The gene discussed is CD8A; the disease is neoplasm.